Teva Pharmaceuticals USA appears as the packager on a U.S. DailyMed label for cephalexin capsules. The cited label identifies 250 mg and 500 mg oral capsules, with distinct NDCs and imprint descriptions. This is evidence for a defined Teva-labeled capsule line, not a claim that Teva currently offers every cephalexin dosage form or that a particular pharmacy has inventory.
For 250 mg capsules, the label lists a Swedish-orange body, gray cap and TEVA/3145 imprint. The 500 mg capsule uses Swedish-orange body and cap with TEVA/3147. The record identifies Teva Pharmaceuticals in Parsippany, New Jersey under 'Manufactured For'; that wording should not be expanded into an unsupported statement about the physical factory. The manufacturer index explains why labels and manufacturing roles differ.
This guide is about reading Teva-specific product records when a pharmacist or patient needs to confirm the drug dispensed. It does not recommend one generic company over another or promise that a given NDC can be ordered. See the generic products overview for broader forms and availability checks for a live pharmacy question. Cephalexin requires a valid U.S. prescription.
The Teva-specific DailyMed record carries set ID 19307ff0-71de-477b-965d-ea243e5ede3a and lists Teva Pharmaceuticals USA, Inc. as the packager. It identifies cephalexin for oral capsule use, rather than liquid or tablet presentations. The prescribing-information revision is dated August 2026, and the label lists application ANDA062702.
A user comparing packages should check the actual label and manufacturer details against the product identifier rather than rely on a general picture of cephalexin. A current record describes the label on file; the pharmacist can establish which product will actually be dispensed.
| Teva label entry | Recorded identifier | What to confirm |
|---|---|---|
| 250 mg capsule | NDC 0093-3145-01 / -05 | TEVA / 3145; gray cap and Swedish-orange body |
| 500 mg capsule | NDC 0093-3147-01 / -05 | TEVA / 3147; Swedish-orange cap and body |
| Application record | ANDA062702 | Approval identifier, not a pharmacy inventory report |
| Other capsule manufacturers | Generic cephalexin | Pharmacist verifies therapeutic equivalence and product match |
| Liquid needed instead | Suspension forms | Do not assume Teva supplied the liquid; obtain authorized directions |
The cited Teva capsule label has two strengths. The 250 mg product is associated with product NDC 0093-3145; the 500 mg product with 0093-3147. The label describes bottles of 100 and 500 capsules under each family. Package count is not the patient's prescribed quantity: the pharmacist dispenses according to the order and applicable packaging procedures.
The 250 mg capsule is identified by a gray cap and Swedish-orange body with the imprint TEVA / 3145. The 500 mg capsule has Swedish-orange cap and body with TEVA / 3147. Those features apply to the cited products, not to every cephalexin capsule made elsewhere. If the appearance differs from a previous fill, ask the dispensing pharmacist to compare the full product identity before use.
The Teva label's August 2026 revision is useful when matching prescribing information and the product description, but a revised label is not evidence of a new launch. The document records ANDA062702, while the product listing provides NDC families that correspond to its packaged capsules. The approval number and NDC serve distinct identification functions.
For regulatory validation, begin with the DailyMed capsule record and consult FDA approval or Orange Book resources as needed. A pharmacy might dispense an approved cephalexin capsule from another company; that does not turn the Teva-specific labeling into evidence about the alternate company's pill imprint or manufacturing site.
Teva NDC 0093-3145 identifies the 250 mg capsule product family and 0093-3147 identifies the 500 mg family in the cited labeling. The appended package suffix distinguishes the cataloged bottle presentation. These digits help a pharmacist trace the package, but do not reveal how many bottles a nearby retailer has on a shelf.
FDA makes a separate regulatory point: merely obtaining an NDC does not itself establish FDA approval. Teva's cited record also carries an ANDA identifier, which is a different kind of evidence. A consumer seeking a manufacturer-specific fill should ask which exact NDC the licensed pharmacy can dispense under the prescription.
DailyMed calls Teva Pharmaceuticals USA the packager of the cited cephalexin capsules; the text also says 'Manufactured For: Teva Pharmaceuticals' with a Parsippany, New Jersey address. Those statements support the labeler's commercial role but do not, by themselves, identify every facility that may participate in production.
If a retailer's invoice contains another company name, compare whether that business is a wholesaler, repackager or actual dispensing pharmacy before attributing physical manufacture. The company-role overview explains how to interpret these terms. Do not use a U.S. address on a product label to claim every unit was manufactured domestically.
The TEVA/3145 and TEVA/3147 imprints are particularly useful because their number combinations distinguish the strength-specific products in the cited record. Colors also differ between the two strengths. A remembered capsule color without an imprint or pharmacy label is too weak to identify an unknown medicine.
Anyone who receives a capsule with unfamiliar markings should check the current pharmacy container, prescription number and exact strength with the pharmacist. Appearance can change after a legitimate generic-manufacturer substitution, but matching cephalexin as the active ingredient is not enough to determine whether a new product's dosage form and directions match the existing order.
The Teva source evaluated here documents oral capsules, not a Teva-branded or Teva-labeled cephalexin suspension. Liquid cephalexin exists elsewhere in U.S. labeling in 125 mg/5 mL and 250 mg/5 mL concentrations, but those products cannot be added to this company's portfolio on the strength of a general drug-category page.
If a patient cannot swallow the dispensed Teva capsule, the pharmacist and prescriber should review an appropriate authorized dosage form. The suspension guide explains the different measurement and storage requirements without implying that the liquid comes from Teva.
A pharmacy may sometimes use another eligible cephalexin capsule manufacturer when a prescription permits generic substitution and the product meets the applicable equivalence requirements. For a Teva-labeled 250 mg capsule prescription, the pharmacist should assess the replacement at the corresponding form and strength, not simply choose any cephalexin item in a catalog.
A substituted manufacturer's product may have a completely different imprint. The pharmacist can compare approval and therapeutic-equivalence information and counsel on label changes. A request for a different ingredient, such as cefadroxil, is not ordinary generic substitution and needs a separate clinical decision.
Someone specifically requesting Teva cephalexin can provide the pharmacist with the documented 250 mg or 500 mg NDC family and confirm the authorized strength and number of units. Ask whether the location can dispense that product, needs to source it or plans to use a different approved generic. Published product records cannot answer a real-time stock question.
For a payment comparison, ask about the exact product, current pharmacy estimate, insurance processing and any applicable service charges. A lower quote for a different manufacturer need not represent a clinical problem if the product is appropriately equivalent, but the pharmacy should still explain the switch before filling. Use the cost guide for matched quotes.
A Teva label identifies a manufacturer-specific cephalexin product, not a safer or stronger antibiotic category. The important clinical considerations remain the prescribed infection, bacterial susceptibility, allergy history, renal function and interactions. Changing the capsule's commercial label does not expand cephalexin coverage to methicillin-resistant staphylococci.
The dispensing professional should confirm correct medication identity and provide appropriate counseling if the package looks different from a previous fill. The prescriber must evaluate treatment suitability; the pharmacist verifies the product the patient actually receives.
To identify the cited Teva capsule, record the prescription's drug, strength and form; verify the TEVA / 3145 or TEVA / 3147 imprint against the appropriate NDC; and compare the final dispensing label with the written directions. If the product offered differs, ask whether the difference is an allowed manufacturer substitution or requires prescriber clarification.
This record-focused checklist does not verify real-time availability, and it does not claim Teva manufacture at a particular factory. For wider company comparisons visit the manufacturer directory; for the actual supply question use a licensed pharmacy and the availability workflow.
The cited Teva capsule label lists 250 mg and 500 mg oral capsules. It does not document a Teva suspension in the same label.
The 250 mg label lists TEVA/3145 with a gray cap; the 500 mg lists TEVA/3147 with an orange cap. Check the dispensing label and pharmacist confirmation.
They are the product NDC families for the 250 mg and 500 mg capsules in the cited DailyMed listing. Package suffixes identify bottle presentations.
No. The cited label identifies Teva as the packager and gives a Manufactured For statement; it should not be used to invent an unspecified factory.
No. A licensed pharmacy must confirm that it can supply the prescribed form, strength and quantity.
A pharmacist may dispense an appropriate approved equivalent if the prescription and applicable state rules permit it. Product matching is specific to dosage form and strength.
The active ingredient may be the same, but dosage forms, measurement and instructions differ. A change of formulation requires professional verification.
No. Cephalexin remains prescription-only in the United States, regardless of the company on its label.